GLP-1 and GLP-1/GIP medications do have some known potential side effects
But with seven more Phase 3 trial results expected throughout 2026 and potential approval projected for 2027, it's the drug that weight loss researchers and patients alike are watching most closely
However, there still remains conflicting data regarding the use of carnitine supplementation to enhance exercise performance due to various factors like dose and timing but also exercise intensity level and training or conditioning of study participants (3)
NAD+ is a coenzyme, not a peptide
Mobile IV: $478 Comprehensive infusion combining hydration, vitamins, amino acids, and antioxidants for total-body wellness and balance
however, direct data linking GLP-1 signaling to improved healthspanthrough measures such as physical function, frailty indices, cognition, or time-to-disabilityremain limited in humans